Three-Pillar Regenerative Protocol
Our structured approach addresses silicosis and asbestosis through synergistic therapeutic modalities, each contributing to disease stabilization and functional preservation.
Core Regenerative Therapy
Umbilical cord mesenchymal stem cells (UC-MSCs) serve as the foundational regenerative component, administered via minimally invasive techniques including intravenous infusion and, when clinically indicated, targeted aerosolized delivery.
- Immunomodulatory properties for fibrotic cascade modulation
- Paracrine signaling to secrete anti-fibrotic factors
- Intravenous and targeted aerosolized administration
- Objective: attenuation of progression, function stabilization
Supportive Physical Therapy
Individualized physical therapy protocol focusing on systemic strength, endurance, and functional capacity. The program targets peripheral muscle groups to reduce overall fatigue and improve the ability to perform daily activities.
- Peripheral muscle strengthening (upper/lower extremities)
- Endurance training to combat deconditioning
- Functional capacity optimization for daily tasks
- Energy conservation techniques
Nutritional Medicine & Supportive Techniques
Targeted antioxidant and anti-inflammatory nutritional support to reduce oxidative burden, alongside minimally invasive techniques such as ultrasound-guided vagal nerve modulation to improve respiratory pattern.
- Personalized anti-inflammatory dietary protocols
- N-acetylcysteine, vitamin D, omega-3 supplementation
- Auricular vagal nerve stimulation
- Myofascial release of accessory respiratory muscles
Clinical Monograph: Mesenchymal Stem Cells in Occupational Lung Disease
Download our comprehensive 24-page clinical monograph detailing mechanisms of action, published preclinical data, and our institutional treatment framework for silicosis and asbestosis. This resource provides objective information about the integral therapeutic approach.
Verifiable medical professional credentials requested
Your information is protected under HIPAA-compliant protocols. The monograph includes current evidence, patient selection criteria, and detailed treatment protocols.
This clinical resource is intended for medical professionals and patients seeking in-depth information.
Eligibility & Optimal Candidate Profile
This protocol is designed for individuals with confirmed diagnosis of silicosis or asbestosis via occupational history and HRCT. Candidates typically present with stable to slowly progressive disease (not acute exacerbation). The protocol is considered an integral supportive approach to conventional care.
All candidates undergo rigorous multidisciplinary evaluation including pulmonology, regenerative medicine, and supportive therapy assessments. Treatment decisions are made on an individual case basis with objective physiological parameters.
Clinical indications:
- Confirmed silicosis/asbestosis via HRCT and occupational history
- Stable to slowly progressive disease (no acute exacerbation)
- FVC ≥ 50% and DLCO ≥ 35% predicted
- No active malignancy within 5 years
- Non-smoker for minimum 6 months
- Age 45-75 years, moderate severity (GOLD stage 2-3)
- Documented rate of FVC decline 150-300 mL/year
- Commitment to comprehensive program including supportive modalities
Formal eligibility determination requires comprehensive clinical assessment. Patients continue prescribed pharmacologic and oxygen therapy under primary pulmonologist's supervision.
HRCT imaging with quantitative fibrosis analysis
Representative image of occupational lung disease assessment
Clinical Protocol & Treatment Course
The treatment protocol consists of an initial intensive phase followed by maintenance intervals. Umbilical cord mesenchymal stem cells are administered via intravenous infusion (target dose 2×10⁸ cells) on days 1, 3, and 5 of the initial phase. Patients demonstrating stabilization or improved functional parameters may continue with quarterly maintenance infusions. Supportive therapies commence concurrently: 12 sessions of supervised physical therapy focusing on systemic conditioning, personalized nutritional intervention (N-acetylcysteine, vitamin D, omega-3), and minimally invasive techniques weekly (vagal nerve stimulation, myofascial release). Objective outcome measures obtained at baseline, 3, 6, and 12 months include PFTs, 6-minute walk distance, St. George's Respiratory Questionnaire, and HRCT at 12 months. Treatment success defined as stabilization of FVC (decline ≤100 mL/year) and improved quality of life metrics.